Impax Laboratories (Nasdaq: IPXL) is expected to report Q2 earnings on July 31. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories' revenues will increase 27.5% and EPS will increase 100.0%.

The average estimate for revenue is $160.5 million. On the bottom line, the average EPS estimate is $0.44.

Revenue details
Last quarter, Impax Laboratories chalked up revenue of $128.6 million. GAAP reported sales were 18% higher than the prior-year quarter's $108.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.52. GAAP EPS of $0.18 for Q1 were 14% lower than the prior-year quarter's $0.21 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 48.7%, 520 basis points worse than the prior-year quarter. Operating margin was 17.5%, 320 basis points worse than the prior-year quarter. Net margin was 9.6%, 320 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $626.7 million. The average EPS estimate is $1.80.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members out of 183 rating the stock outperform, and 12 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is hold, with an average price target of $24.89.

Over the decades, small-cap stocks, like Impax Laboratories have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.